Group 1 - The National Healthcare Security Administration has issued the "Interim Measures for Payment Management by Disease," promoting payment reform and clarifying total budget management, grouping adjustment cycles, and payment standard calculations [1] - The preliminary list of innovative drugs for medical insurance and commercial insurance for 2025 has been published, with several cancer drugs (such as bispecific antibodies, CAR-T therapies, and ADCs) and new chronic disease drugs passing the review, indicating potential rapid market release for these innovative drugs [1] - Semaglutide has received FDA approval for the treatment of metabolic dysfunction-associated fatty liver disease (MAFLD), further expanding the application scenarios for GLP-1 drugs [1] Group 2 - The Guotai Junan Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which can experience daily fluctuations of up to 20%. This index selects listed companies engaged in biotechnology, innovative pharmaceuticals, and medical services from the ChiNext market, focusing on companies with core R&D capabilities and high growth characteristics [1]

Group 1 - The Hang Seng Innovation Drug ETF (159316) has shown active trading with a turnover of 31.05% and a transaction volume of 499 million yuan as of August 25, 2025, indicating a strong market interest [1] - As of August 22, 2025, the latest scale of the Hang Seng Innovation Drug ETF reached 1.598 billion yuan, marking a new high since its inception [1] - In the past five trading days, the Hang Seng Innovation Drug ETF experienced net inflows on four occasions, totaling 330 million yuan [1] Group 2 - The Hang Seng Innovation Drug ETF closely tracks the Hang Seng Innovation Drug Index, which reflects the performance of Hong Kong-listed companies involved in the research, development, and production of innovative drugs [2] - The Hang Seng Hong Kong Stock Connect Innovation Drug Index (HSSCIHKI) is the only "100% purity" innovative drug index in the market, focusing on companies holding core patents and directly participating in innovative drug R&D and commercialization [2] - The Hang Seng Innovation Drug ETF (159316) is currently the only ETF product tracking the Hang Seng Innovation Drug Index, providing high elasticity and scarcity, thus helping investors seize the investment opportunities in the Hong Kong innovative drug sector [2] Group 3 - Domestic large pharmaceutical companies have stabilized their generic drug business after the impact of centralized procurement, and the results of their innovative transformation are significant [1] - Since 2025, Heng Rui Medicine has disclosed three BD collaborations with a total upfront payment of approximately 720 million USD, with potential total transaction amounts exceeding 13.7 billion USD, indicating that BD could become a sustainable income source [1] - China Biopharmaceutical announced in June that it would achieve a "landmark heavyweight external authorization transaction," and in July, it fully acquired Li Xin Pharmaceutical for a net amount of 500 million USD, enhancing its dual antibody/ADC platform and international R&D capabilities [1] - Recently, Heng Rui Medicine plans to repurchase up to 2 billion yuan, while Sheng Sen Pharmaceutical intends to repurchase up to 500 million yuan, demonstrating companies' confidence in future development through intensive buybacks and increases [1]

Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, benefits from the depreciation of the RMB and its focus on innovative drugs and biopharmaceuticals, with a significant portion of its revenue coming from overseas markets [2][3]. Company Overview - Established in 1998, Haiprime is headquartered in Shenzhen and operates with both A and H share financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company's main business revenue composition includes: formulations (56.55%), heparin sodium and low molecular weight heparin raw materials (20.25%), CDMO (19.58%), and others (3.63%) [7]. Financial Performance - For the period from January to March 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, with a growth of 1.00% [7]. - As of March 31, 2025, Haiprime has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Position - Haiprime's overseas revenue accounts for 93.04% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is positioned within the pharmaceutical and biopharmaceutical sectors, with a focus on vaccines, innovative drugs, and raw materials [7]. Stock Performance - On August 25, Haiprime's stock increased by 1.97%, with a trading volume of 115 million yuan and a market capitalization of 19.764 billion yuan [1]. - The average trading cost of the stock is 11.46 yuan, with current price levels between resistance at 13.61 yuan and support at 13.40 yuan, indicating potential for range trading [6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company's innovative achievements are driving revenue growth, with both internal development and external licensing progressing simultaneously [12] - In the first half of 2025, the company achieved revenue of 15.76 billion yuan (up 15.88% year-on-year) and a net profit attributable to shareholders of 4.45 billion yuan (up 29.67% year-on-year) [12][14] - The company has a robust R&D pipeline with over 100 self-innovated products in clinical development and more than 400 clinical trials ongoing domestically and internationally [13] Summary by Sections Financial Performance - In the first half of 2025, the company reported revenue of 157.61 billion yuan, a year-on-year increase of 15.88%, and a net profit of 44.50 billion yuan, up 29.67% year-on-year [12][14] - The second quarter alone saw revenue of 85.56 billion yuan (up 12.53% year-on-year) and a net profit of 25.76 billion yuan (up 24.88% year-on-year) [12] Innovation and Licensing - Revenue from innovative drugs and licensing reached 95.61 billion yuan, accounting for 60.66% of total revenue, with innovative drug sales contributing 75.70 billion yuan [12] - The company confirmed licensing agreements with MSD and IDEAYA, receiving upfront payments of 200 million USD and 75 million USD, respectively [12] - A new agreement with GSK for overseas licensing of HRS-9821 and up to 11 projects will yield an upfront payment of 500 million USD [12] R&D Pipeline - The company has a deep R&D pipeline with over 100 innovative products in clinical development and 400 clinical trials ongoing [13] - Six Class 1 innovative drugs were approved for market in the first half of 2025, with multiple new indications also receiving approval [13] Future Projections - Revenue projections for 2025-2027 are 315.41 billion yuan, 353.04 billion yuan, and 403.88 billion yuan, with year-on-year growth rates of 12.71%, 11.93%, and 14.40% respectively [14] - Net profit projections for the same period are 73.07 billion yuan, 81.92 billion yuan, and 94.24 billion yuan, with growth rates of 15.31%, 12.11%, and 15.04% respectively [14]

证券研究报告 创新药黄金赛道梳理之PD-1（PD-L1）/VEGF双抗 生物医药行业强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PINGAN.C ...

Core Viewpoint - The company reported its 1H25 performance, showing a slight decline in revenue but a positive trend in net profit for the second quarter, indicating stabilization in its existing business and potential for future growth through new product launches [1][2][4]. Financial Performance - 1H25 revenue was 3.369 billion yuan, a year-on-year decrease of 0.4% - Net profit attributable to shareholders was 691 million yuan, down 0.9%, while the net profit excluding non-recurring items was 662 million yuan, up 2.3% - 2Q25 revenue reached 1.633 billion yuan, an increase of 11.7% year-on-year - 2Q25 net profit attributable to shareholders was 310 million yuan, up 45.0%, and net profit excluding non-recurring items was 325 million yuan, up 70.3% [1]. Business Segments - Medical device revenue for 1H25 was 1.776 billion yuan, a year-on-year increase of 1.3% - Coronary revenue increased by 3.6% - Structural heart disease revenue rose by 32.1% - Surgical anesthesia revenue decreased by 10.29% - In-vitro diagnostics revenue fell by 17.35% [2]. - Pharmaceutical revenue was 1.117 billion yuan, a year-on-year decrease of 1.5%, but increased by 79.3% quarter-on-quarter - The revenue from formulations (generic drugs) was 975 million yuan, up 3.9% year-on-year, and 1.42 billion yuan from raw materials, down 27.4% year-on-year [2]. - Medical services and health management revenue was 475 million yuan, down 4.1% year-on-year [2]. New Product Development - The company is focusing on several growth areas: - Innovative drugs: The subsidiary Shanghai Minwei Biotech is developing a triple receptor agonist candidate, MWN101, which has completed Phase II clinical trials for obesity and type 2 diabetes [3]. - Consumer healthcare: Products like polylactic acid facial fillers and sodium hyaluronate injections have received approval and are in commercialization [3]. - Neuroscience: The company anticipates approval for its deep brain stimulation device in Q4 2025 and is exploring further developments in brain-computer interfaces and artificial intelligence [3]. Profit Forecast and Valuation - The company maintains its profit forecasts for 2025/26, with a current price corresponding to a P/E ratio of 27/24 times - The target price has been raised by 60% to 24 yuan, indicating a 32% upside potential from the current price, corresponding to a P/E ratio of 35/32 times for 2025/26 [4].

Group 1 - The Hong Kong stock market saw significant gains, with the Hang Seng Index rising over 2% to reach a new high since 2021, and the Hang Seng Tech Index increasing by over 3% [1] - Technology stocks, non-ferrous metals, and domestic property stocks experienced broad-based increases, while new consumption concepts showed mixed performance [1] - The Hang Seng Tech Index ETF (513180) followed the index's upward trend, with notable gains from stocks like NIO, Alibaba, Baidu, NetEase, Horizon Robotics, and Lenovo, with NIO surging over 16% at one point [1] Group 2 - Improved liquidity prospects have led several institutions to be optimistic about the future performance of the Hang Seng Tech Index [1] - According to China Merchants Securities, the market is currently in a bull market phase II, characterized by capital-driven growth and a focus on key sectors, recommending attention to innovative pharmaceuticals, CXO, domestic computing power, robotics, and domestic AI agents [1] - Huatai Securities noted that the Hang Seng Tech Index remains relatively undervalued, and with overseas liquidity easing and AI technology themes gaining traction, it may experience significant upward momentum [1][2]

Policy Developments - The National Healthcare Security Administration held a training session on accelerating the construction of a long-term care insurance system, emphasizing the need for a unified and independent insurance model, multi-channel funding, and digital management to enhance service efficiency [2] Drug and Medical Device Approvals - Kangyuan Pharmaceutical received clinical trial approval for its Jin Zhen oral liquid to treat children's influenza, indicating a promising market outlook for this pediatric traditional Chinese medicine [4] - AstraZeneca's Datroway® was approved for use in treating hormone receptor-positive, HER2-negative breast cancer in adults who have previously undergone endocrine therapy and at least one line of chemotherapy, based on positive results from a global Phase III study [5] - Xianju Pharmaceutical's dexamethasone acetate tablets passed the consistency evaluation for generic drugs, which will enhance the company's market competitiveness [6] Financial Reports - Pian Zai Huang reported a 4.81% decline in total revenue to 5.379 billion yuan and a 16.22% decrease in net profit to 1.442 billion yuan for the first half of 2025, while advancing multiple new drug projects [8] - Wandong Medical achieved a 20.46% increase in revenue to 843 million yuan, but net profit fell by 39.46% to 51.3 million yuan, despite a 59.16% rise in R&D investment [9] - Huangshan Capsule reported a 3.66% increase in revenue to 244 million yuan and a 19.78% rise in net profit to 35.6 million yuan for the first half of 2025 [10] Capital Markets - Kexing Pharmaceutical announced plans to list on the Hong Kong Stock Exchange to enhance its international competitiveness and optimize its capital structure [12] - Tongce Medical acquired a 100% stake in Shanghai Congji Dental Clinic for 46 million yuan, aiming to enhance brand presence in the high-end market [13] Industry Developments - China's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs under development, reflecting significant growth driven by policy, technology, and capital influx [15]

Group 1 - The market showed a strong performance on August 25, with the ChiNext Index leading the gains and a significant increase in trading volume, reaching 2.08 trillion yuan, up 567.8 billion yuan from the previous trading day [1] - The Tianhong ChiNext ETF (159977) rose by 2.26%, hitting a new high during the session, with notable gains in constituent stocks such as Jinli Permanent Magnet and Lepu Medical [1] - Huatai Securities believes that ample liquidity remains the main foundation for the market, suggesting that the market is entering an upward trend, supported by improvements in domestic fundamentals, liquidity, and overseas conditions [1] Group 2 - Huabao Securities noted that market enthusiasm is high, with continued inflow of new funds and a sustained profit-making effect, indicating that the A-share market is likely to continue its upward trend unless there are policy interventions [2] - Caixin Securities highlighted that the market's profit-making effect may attract new funds quickly, especially after the Shanghai Composite Index breaks strong resistance levels, although short-term fluctuations may occur [2] - The Tianhong Sci-Tech ETF (589860) closely tracks the Sci-Tech Index, which covers approximately 97% of the Sci-Tech board's market capitalization, emphasizing its strong growth attributes [3] Group 3 - The Tianhong A500 ETF (159360) tracks the CSI 500 Index, which selects 500 stocks with strong market representation across various industries, balancing large-cap stocks while covering core industry leaders [3] - The index's compilation incorporates criteria such as mutual connectivity and ESG, facilitating long-term capital allocation in A-share assets [3]

Core Viewpoint - The Chinese innovative drug industry is rapidly developing under policy support and globalization, with leading companies like BeiGene and HengRui Medicine making significant advancements through high R&D investments and dense pipelines [2][3]. Policy and Market Dynamics - The National Healthcare Security Administration initiated the 2025 medical insurance directory adjustment, emphasizing support for innovative drugs, which has boosted industry confidence [3]. - In the first half of 2025, the transaction amount for Chinese innovative drug BD reached $48.448 billion, highlighting accelerated globalization and international cooperation [3]. Company Performance Overview - **BeiGene**: Achieved revenue of 17.518 billion yuan, a 46% increase year-on-year, with a net profit of 450 million yuan, marking its first profitable half-year since listing. Its core product, Tislelizumab, generated sales of 2.643 billion yuan, up 20.6% [7]. - **HengRui Medicine**: Reported innovative drug sales and licensing income of 9.561 billion yuan, accounting for 60.66% of total revenue, with core innovative drug sales driving growth [8]. - **Hansoh Pharmaceutical**: Revenue reached 7.434 billion yuan, a 14.3% increase, with innovative drug sales contributing 82.7% [8]. - **Innovent Biologics**: Generated over 5.2 billion yuan in product revenue, a growth of over 35%, and completed a significant financing project [8]. - **China National Pharmaceutical Group**: Revenue of 17.57 billion yuan, with a net profit of 3.39 billion yuan, a 140.2% increase year-on-year [8]. - **East China Pharmaceutical**: Achieved revenue of 7.317 billion yuan, a 9.24% increase, with R&D investment rising significantly [9]. R&D Pipeline and Trends - The innovative drug sector is experiencing a concentrated R&D phase, with leading companies accelerating their pipeline development [10]. - **HengRui Medicine**: Six first-class innovative drugs were approved during the reporting period, with a robust pipeline including multiple drugs in various clinical stages [13]. - **BeiGene**: Continues to advance in ADC and bispecific antibodies, enhancing its international competitiveness [13]. - **Innovent Biologics**: Has 52 drugs in clinical stages, focusing on various innovative targets [13]. Role of Scientific Instrumentation - Scientific instrument manufacturers are transitioning from supporters to key enablers in the innovative drug sector, providing comprehensive technical support throughout the drug development process [3][14]. - **Waters Corporation**: Reported an 11% growth in pharmaceutical business, with a 70% increase in GLP-1 related income [15]. - **Agilent Technologies**: Increased revenue in life sciences and diagnostics, establishing strategic partnerships to enhance drug development capabilities [16]. - **Thermo Fisher Scientific**: Achieved $6 billion in laboratory product sales, exceeding market expectations, and providing comprehensive services for drug development [16]. Industry Outlook - The rapid development of new molecular types like antibodies and ADCs is creating significant challenges in quality management, fostering a deep coupling between innovative drug companies and scientific instrument manufacturers [18].